Core-shell nanocarriers for cancer therapy. Part I: Biologically oriented design rules

Expert Opinion on Drug Delivery

Volumn 11, Issue 2, 2014, Pages 283-297

  D'Angelo, Ivana ^a   Conte, Claudia ^b   Miro, Agnese ^b   Quaglia, Fabiana ^b   Ungaro, Francesca ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Administration route; Biological barriers; Cancer; Core shell nanocarriers; Nanomedicine

Indexed keywords

NANOCARRIER; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; PROTEIN INTERACTION; REVIEW; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84892701252     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.868881     Document Type: Review

References (127)

1. Jain KK. Advances in the field of nanooncology. BMC Med 2010;8:83
2. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9
3. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 2012;7:1577-90
4. Bourzac K. Nanotechnology: carrying drugs. Nature 2012;491:S58-60
5. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
6. Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012;12:39-50
7. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012;64:1394-416
8. Huang HC, Barua S, Sharma G, et al. Inorganic nanoparticles for cancer imaging and therapy. J Control Release 2011;155:344-57
9. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9:257-88
10. Caldorera-Moore ME, Liechty WB, Peppas NA. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res 2011;44:1061-70
11. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010;62:1052-63
12. Park K, Lee S, Kang E, et al. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater 2009;19:1553-66
13. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010;62:1064-79
14. Conte C, d'Angelo I, Miro A, et al. Core-shell nanocarriers for cancer. Part II: current trends and novel concepts in polymeric nanoparticles. Expert Opin Drug Deliv 2013;In press
15. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
16. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
17. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60
18. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51
19. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012;164:138-44
20. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomophysiological perspective. J Control Release 2012;161:152-63
21. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012;7:779-86
22. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011;8:343-57
23. Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008;105:14265-70
24. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007;2:249-55
25. Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev 2006;35:1095-104
26. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 2009;26:235-43
27. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102
28. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012;52:481-503
29. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15
30. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010;55-86
31. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 2012;64:316-26
32. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354:56-62
33. bu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 2013;172:38-47
34. Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012;9:1319-23
35. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013;30:1729-34
36. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455-65
37. Denison TA, Bae YH. Tumor heterogeneity and its implication for drug delivery. J Control Release 2012;164:187-91
38. Li YH, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012;64:29-39
39. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008;99:392-7
40. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010
41. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135-46
42. Florence AT. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. J Control Release 2012;164:115-24
43. Florence AT. Reductionism and complexity in nanoparticle-vectored drug targeting. J Control Release 2012;161:399-402
44. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010;141:265-76
45. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87
46. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012;164:108-14
47. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198-205
48. Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8:137-43
49. Lee H, Fonge H, Hoang B, et al. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010;7:1195-208
50. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77-104
51. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 1991;41:5-23
52. Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol 2012;7:62-8
53. Mahon E, Salvati A, Baldelli Bombelli F, et al. Designing the nanoparticlebiomolecule interface for targeting and therapeutic delivery. J Control Release 2012;161:164-74
54. Tian L, Bae YH. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf B Biointerfaces 2012;99:116-26
55. Abulateefeh SR, Spain SG, Aylott JW, et al. Thermoresponsive polymer colloids for drug delivery and cancer therapy. Macromol Biosci 2011;11:1722-34
56. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 2012;64:866-84
57. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9:615-27
58. Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 2011;63:640-58
59. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003;55:199-215
60. Tietze R, Lyer S, Durr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond) 2012;7:447-57
61. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009;61:467-77
62. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008;21:61-70
63. Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 2012;7:1551-72
64. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61:158-71
65. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96
66. Ungaro F, d'Angelo I, Miro A, et al. Engineered PLGA nano-and microcarriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012;64:1217-35
67. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009;61:75-85
68. Lai SK, Wang YY, Wirtz D, Hanes J. Micro-and macrorheology of mucus. Adv Drug Deliv Rev 2009;61:86-100
69. Ibrahim BM, Park S, Han B, Yeo Y. A strategy to deliver genes to cystic fibrosis lungs: a battle with environment. J Control Release 2011;155:289-95
70. Ibrahim BM, Tsifansky MD, Yang Y, Yeo Y. Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opin Drug Deliv 2011;8:451-66
71. Sanders NN, De Smedt SC, Van RE, et al. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000;162:1905-11
72. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 2003;278:50393-401
73. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74
74. Henning A, Schneider M, Nafee N, et al. Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv 2010;23:233-41
75. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci 2011;11:748-64
76. Olmsted SS, Padgett JL, Yudin AI, et al. Diffusion of macromolecules and viruslike particles in human cervical mucus. Biophys J 2001;81:1930-7
77. Mura S, Hillaireau H, Nicolas J, et al. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011;12:4136-43
78. Ungaro F, d'Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012;157:149-59
79. Tang BC, Dawson M, Lai SK, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009;106:19268-73
80. Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013;34:3439-46
81. Suk JS, Lai SK, Boylan NJ, et al. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 2011;6:365-75
82. Sanders N, Rudolph C, Braeckmans K, et al. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 2009;61:115-27
83. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 2012;64:1-15
84. Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv 2007;4:607-20
85. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70
86. Tseng CL, Wang TW, Dong GC, et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007;28:3996-4005
87. Tseng CL, Wu SY, Wang WH, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008;29:3014-22
88. Tseng CL, Su WY, Yen KC, et al. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009;30:3476-85
89. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007;2:495-9
90. Rudolph C, Gleich B, Flemmer AW. Magnetic aerosol targeting of nanoparticles to cancer: nanomagnetosols. Methods Mol Biol 2010;624:267-80
91. Verma NK, Crosbie-Staunton K, Satti A, et al. Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology 2013;11:1-11
92. Conti DS, Bharatwaj B, Brewer D, da Rocha SR. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J Control Release 2012;157:406-17
93. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 2008;5:629-39
94. Pulliam B, Sung JC, Edwards DA. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv 2007;4:651-63
95. Al-Hallak MH, Sarfraz MK, Azarmi S, et al. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther Deliv 2011;2:1313-24
96. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002;99:12001-5
97. Tomoda K, Ohkoshi T, Hirota K, et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces 2009;71:177-82
98. Roa WH, Azarmi S, Al-Hallak MH, et al. Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J Control Release 2011;150:49-55
99. Malingre MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drugs 2001;19:155-62
100. Bebawy M, Sze DM. Targeting Pglycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets 2008;8:47-52
101. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001;280:G922-9
102. Cai Z, Wang Y, Zhu LJ, Liu ZQ. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 2010;11:197-207
103. Mei L, Zhang Z, Zhao L, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev 2013;65:880-90
104. Feng SS. Nonoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev Med Devices 2004;1:115-25
105. Desai MP, Labhasetwar V, Walter E, et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997;14:1568-73
106. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70
107. Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 2011;409:111-20
108. Saremi S, Atyabi F, Akhlaghi SP, et al. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomedicine 2011;6:119-28
109. Kanwar JR, Mahidhara G, Kanwar RK. Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine 2012;7:1521-50
110. Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010;138:843-53
111. Laroui H, Rakhya P, Xiao B, et al. Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders. Dig Liver Dis 2013;12):995-1002
112. Zabaleta V, Ponchel G, Salman H, et al. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm 2012;81:514-23
113. Kruijtzer CMF, Beijnen JH, Schellens JHM. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-30
114. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012;159:14-26
115. Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 2011;28:1819-30
116. Bajaj G, Yeo Y. Drug delivery systems for intraperitoneal therapy. Pharm Res 2010;27:735-8
117. Bajaj G, Kim MR, Mohammed SI, Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release 2012;158:386-92
118. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011;63:470-91
119. Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin Drug Deliv 2012;9:783-804
120. Rancan F, Papakostas D, Hadam S, et al. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res 2009;26:2027-36
121. Zhang W, Gao J, Zhu Q, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm 2010;402:205-12
122. Rancan F, Papakostas D, Hadam S, et al. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res 2009;26:2027-36
123. Rosado C, Silva C, Reis CP. Hydrocortisone-loaded poly(epsiloncaprolactone) nanoparticles for atopic dermatitis treatment. Pharm Dev Technol 2013;18:710-18
124. Zhang LW, Yu WW, Colvin VL, Monteiro-Riviere NA. Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes. Toxicol Appl Pharmacol 2008;228:200-11
125. Batheja P, Sheihet L, Kohn J, et al. Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J Control Release 2011;149:159-67
126. Gupta S, Gabrani R, Ali J, Dang S. Exploring novel approaches to vaginal drug delivery. Recent Pat Drug Deliv Formul 2011;5:82-94
127. Cu Y, Booth CJ, Saltzman WM. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release 2011;156:258-64